Systemic Lupus Erythematosus: What Every Clinician Needs to Know

Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease that disproportionately affects women of reproductive age and is associated with substantial morbidity, premature mortality, and racial and ethnic disparities. Advances in diagnosis and immunosuppressive therapy have improved survival, yet patients remain at increased risk for kidney failure, cardiovascular disease, infection, pregnancy complications, and treatment related damage. Primary care and hospital-based clinicians are often the first point of contact and are central to early recognition, evaluation, and comorbidity management. Informed by a comprehensive literature review, this article links key SLE pathobiology to current therapies, including loss of immune tolerance to nuclear antigens, immune complex mediated tissue injury, and type I interferon driven inflammation. We outline a practical diagnostic approach that emphasizes pattern recognition across organ systems, judicious use and interpretation of antinuclear antibody testing, and timely referral to rheumatology. We highlight the distinction between disease activity and cumulative damage and describe a treat to target strategy focused on low disease activity or remission with minimal glucocorticoid exposure. Organ based sections address common renal, musculoskeletal, mucocutaneous, cardiopulmonary, hematologic, neuropsychiatric, and reproductive manifestations, with an emphasis on what clinicians should screen for, manage directly, and refer urgently. We review major comorbidities, including antiphospholipid syndrome, cardiovascular disease, osteoporosis, infection risk, and pediatric onset SLE, and address pregnancy and contraception. Throughout, we emphasize hydroxychloroquine as foundation therapy, a glucocorticoid sparing mindset, aggressive prevention of cardiovascular and bone disease, and structured collaboration between rheumatology and non-rheumatology clinicians to improve outcomes in SLE.